Ergänzende Abbildung 2 aus Differentialverteilung des DNA-PKcs-Inhibitors Peposertib selektiv radiosensibilisiert patientenabgeleitete Melanom-Hirnmetastasen-Xenotransplantate

Ji et al. (Do,) untersuchten diese Fragestellung.

www.synapsesocial.com/papers/68e6be8ab6db64358763e1ca — DOI: https://doi.org/10.1158/1535-7163.25735658.v1

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Supplementary Figure 2 from Differential Distribution of the DNA-PKcs Inhibitor Peposertib Selectively Radiosensitizes Patient-derived Melanoma Brain Metastasis Xenografts· 2024
2. Supplementary Figure 2 from Differential Distribution of the DNA-PKcs Inhibitor Peposertib Selectively Radiosensitizes Patient-derived Melanoma Brain Metastasis Xenografts· 2024
3. Supplementary Figure 2 from Differential Distribution of the DNA-PKcs Inhibitor Peposertib Selectively Radiosensitizes Patient-derived Melanoma Brain Metastasis Xenografts· 2024
4. Supplementary Figure 1 from Differential Distribution of the DNA-PKcs Inhibitor Peposertib Selectively Radiosensitizes Patient-derived Melanoma Brain Metastasis Xenografts· 2024
5. Supplementary Figure 1 from Differential Distribution of the DNA-PKcs Inhibitor Peposertib Selectively Radiosensitizes Patient-derived Melanoma Brain Metastasis Xenografts· 2024